![<?echo $_SERVER['SERVER_NAME'];?>](/template/twentyseventeen/skin/images/header.jpg)
According to the Nikkei Industry News recently reported that Japanese medium-sized pharmaceutical companies have started to strengthen their businesses in China.
Kyowa Fertilizer plans to start its Suzhou pharmaceutical factory in 2007. It will start with product packaging. In 2009, it will import raw materials from Japan and make tablets to produce finished drugs. In addition to the antihypertensive drug Benedipine, which has been sold in China, the plant is also preparing to produce the anti-allergic drug "Olopatadine." The drug is currently undergoing human trials for clinical trials designed to confirm its safety and effectiveness.
Kyowa Fertilizer plans to implement one-stop production from raw pharmaceutical tablet production to packaging in China in 2009. With the investment in new products, the company is also preparing to increase the number of pharmaceutical representatives from the current 80 to about 100.
In addition, Nissenchi Pharmaceutical Co., Ltd. will also employ 100 pharmaceutical representatives in China in 2009.
Analysts pointed out that as industry experts predict that the size of China's medical drug market will continue to expand in the next few years, following the large-scale pharmaceutical companies, Japanese medium-sized pharmaceutical companies are accelerating the development of this huge market.
Kyowa Fertilizer plans to start its Suzhou pharmaceutical factory in 2007. It will start with product packaging. In 2009, it will import raw materials from Japan and make tablets to produce finished drugs. In addition to the antihypertensive drug Benedipine, which has been sold in China, the plant is also preparing to produce the anti-allergic drug "Olopatadine." The drug is currently undergoing human trials for clinical trials designed to confirm its safety and effectiveness.
Kyowa Fertilizer plans to implement one-stop production from raw pharmaceutical tablet production to packaging in China in 2009. With the investment in new products, the company is also preparing to increase the number of pharmaceutical representatives from the current 80 to about 100.
In addition, Nissenchi Pharmaceutical Co., Ltd. will also employ 100 pharmaceutical representatives in China in 2009.
Analysts pointed out that as industry experts predict that the size of China's medical drug market will continue to expand in the next few years, following the large-scale pharmaceutical companies, Japanese medium-sized pharmaceutical companies are accelerating the development of this huge market.
Ribbed Drive Belt,Automotive V Ribbed Belt,Multi Rib V Belt,Poly V Ribbed Belt
ZHEJIANG AOSITE AUTO PARTS CO.,LTD , https://www.aositebelt.com